Arcus Biosciences Inc RCUS
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of Arcus Biosciences Inc shares you hold and we'll calculate your dividend payments:
Sign up for Arcus Biosciences Inc and we'll email you the dividend information when they declare.
Add Arcus Biosciences Inc to receive free notifications when they declare their dividends.
Your account is set up to receive Arcus Biosciences Inc notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no Arcus Biosciences Inc dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0c | — |
| 2007 | 0.0c | 0% |
| 2008 | 0.0c | 0% |
| 2009 | 0.0c | 0% |
| 2010 | 0.0c | 0% |
| 2011 | 0.0c | 0% |
| 2012 | 0.0c | 0% |
| 2013 | 0.0c | 0% |
| 2014 | 0.0c | 0% |
| 2015 | 0.0c | 0% |
| 2016 | 0.0c | 0% |
| 2017 | 0.0c | 0% |
| 2018 | 0.0c | 0% |
| 2019 | 0.0c | 0% |
| 2020 | 0.0c | 0% |
| 2021 | 0.0c | 0% |
| 2022 | 0.0c | 0% |
| 2023 | 0.0c | 0% |
| 2024 | 0.0c | 0% |
| 2025 | Sign Up Required | |
Arcus Biosciences Inc Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 12 March 2024
- 52 Week Low
- 0.0% on 12 March 2024
- Next Ex-Div-Date Countdown
- Sign Up Required
About Arcus Biosciences Inc
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on developing cancer therapies. The Company's six investigational products are in the clinical development, with its molecule, an anti-TIGIT antibody, which is in two phase III registrational studies. The Company's differentiated combination therapies are developing to treat multiple large tumor types, including lung, colorectal, prostate and pancreatic cancers. Its clinical development pipeline includes Domvanalimab, AB308, Etrumadenant, Quemliclustat, Zimberelimab and AB521. Domvanalimab is its Fc-silent anti-TIGIT monoclonal antibody. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells (dendritic cells, macrophages), mediated by the A2a and A2b receptors. Quemliclustat is an extremely potent and selective small-molecule CD73 inhibitor. Zimberelimab is its anti-PD-1 antibody.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United States
- Share Price
- $9.90 (yesterday's closing price)
- Shares in Issue
- 105 million
- Market Cap
- $1.0bn
- 0
- Market Indices
- none
